GeneDx (WGS) Projected to Post Quarterly Earnings on Monday

GeneDx (NASDAQ:WGS) is anticipated to issue its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect GeneDx to post earnings of $0.11 per share and revenue of $120.80 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 8:30 AM ET.

GeneDx Stock Performance

Shares of WGS stock opened at $82.06 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of 911.78 and a beta of 2.00. GeneDx has a one year low of $55.17 and a one year high of $170.87. The company has a 50 day moving average price of $112.39 and a 200 day moving average price of $124.65.

Analyst Ratings Changes

WGS has been the topic of several research reports. Wells Fargo & Company raised GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 target price on the stock in a research report on Monday, February 9th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. BTIG Research lifted their price objective on GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Guggenheim reiterated a “buy” rating and set a $170.00 target price (up previously from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Finally, Canaccord Genuity Group increased their target price on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $146.43.

Insider Buying and Selling

In other news, COO Bryan Dechairo sold 5,961 shares of GeneDx stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $85.70, for a total transaction of $510,857.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Katherine Stueland sold 1,653 shares of the business’s stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $94.00, for a total transaction of $155,382.00. Following the transaction, the chief executive officer directly owned 16,458 shares in the company, valued at approximately $1,547,052. The trade was a 9.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 68,961 shares of company stock worth $10,027,891 in the last ninety days. 29.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On GeneDx

A number of large investors have recently added to or reduced their stakes in WGS. Franklin Resources Inc. increased its stake in GeneDx by 101.9% during the 3rd quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock worth $73,412,000 after buying an additional 343,954 shares during the period. Invesco Ltd. grew its stake in shares of GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock valued at $102,288,000 after acquiring an additional 292,394 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of GeneDx by 717.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 258,745 shares of the company’s stock valued at $33,652,000 after acquiring an additional 227,088 shares in the last quarter. ARK Investment Management LLC increased its position in shares of GeneDx by 35.3% during the fourth quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock worth $78,629,000 after acquiring an additional 157,582 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of GeneDx by 76.2% in the second quarter. Ameriprise Financial Inc. now owns 255,931 shares of the company’s stock worth $23,625,000 after acquiring an additional 110,684 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.